As Bcl‐2 family proteins appear to be an attractive drug target for cancer therapy, it is therefore imperative to explore platycodin D for its potential to target Bcl‐2 family protein in a wide variety of cancer cells both in vitro and in vivo cancer models to develop it into a promising chemotherapeutic drug. The gene discussed is BCL2; the disease is cancer.